



Revisions to APF25

Cautionary advisory labels

Revisions to Table 2.2 Recommended cautionary advisory labels for medicines
Revised CAL recommendations for the following medicines are shown in the table below.

Medicine	Revised ancillary label (number) and/or additional instruction (letter)
Acetazolamide	8, 10a, 12
Adalimumab	6 (except syringe in use), 7b*, 13
Atazanavir	4b, 5, B
Chlorpromazine	Oral solution: 1, 8, 9 (long-term regular therapy), 13, 16, 21 Tablet: 1, 8, 9 (long-term regular therapy), 13, 16, 21, A
Ciclosporin	Capsule: 5, 8, 9, 18, 21, A Eye drop: 13, J* Oral solution: 5, 7b (60 days), 8, 9, 18, 21
Colchicine	5, 13, 18, 21, A
Emtricitabine, tenofovir disoproxil	7b* (30 days), 12†, 13, B
Everolimus	Dispersible tablet: 5, 8, 9, 13, 18, 21 Tablet: 5, 8, 9, 13, 18, 21, A
Interferon alfa-2a	6, 12 (delete from <i>Table 2.3 Hazardous medicines</i>)
Interferon gamma-1b	6, 12 (delete from <i>Table 2.3 Hazardous medicines</i>)
Melatonin	2, 12, A
Methylphenidate	5, 12, 13, 21, A (add to <i>Table 2.3 Hazardous medicines</i> with superscript 'c')
Naproxen	Enteric-coated tablet/modified-release tablet: 10a, 12†, 19b, A, B Oral suspension: 10a, 12†, 19b, B, J Tablet: 10a, 12†, 19b, B
Paliperidone	1, 16
Peginterferon alfa-2a	6, 12 (delete from <i>Table 2.3 Hazardous medicines</i>)
Perampanel	Oral suspension: 1, 7b (90 days), 9, J Tablet: 1, 9
Posaconazole	Modified-release tablet: 5, 12, A Oral suspension: 5, 12, B, J
Rasagiline	5, 9, 12, 21, A
Risperidone	Oral solution/tablet: 1, 16 Orally disintegrating tablet: 1, 13, 16
Terbinafine	Cream/gel/topical solution: K Tablet: 5, 8, 12, 13, D
Teriparatide	6, 7b (28 days), 16†
Ursodeoxycholic acid	Capsule/tablet: 4a (delete dairy products and mineral supplements), A Oral suspension: 4a (delete dairy products and mineral supplements), 7b (4 months), J